Replimune Group Stock In The News

REPL Stock  USD 11.66  0.20  1.69%   
Our overall analysis of Replimune's news coverage and content from conventional and social sources shows investors' bearish mood towards Replimune Group. The specific impact of Replimune news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Replimune's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Replimune headlines in addition to utilizing other, more conventional financial analysis modules. Check out Replimune Backtesting and Replimune Hype Analysis.

Replimune Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2025/03/07/3039229/0/en/Replimune-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Neutral
Macroaxis News: globenewswire.com
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2025/02/07/3023004/0/en/Replimune-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Neutral
Yahoo News
Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
https://finance.yahoo.com/news/morgan-stanleys-strategic-reduction-replimune-011124791.html
 Bullish
Yahoo News
12 Best Medical Stocks to Buy Under $10
https://finance.yahoo.com/news/12-best-medical-stocks-buy-083027104.html
 Bullish
Yahoo News
15 Small-Cap Stocks with High Potential
https://finance.yahoo.com/news/15-small-cap-stocks-high-155453758.html
 Bullish
Yahoo News
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
https://finance.yahoo.com/news/disco-pharmaceuticals-launches-surfaceome-company-085900330.html
 Neutral
Yahoo News
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
https://finance.yahoo.com/news/replimune-present-42nd-annual-j-130000436.html
 Bearish
Yahoo News
An Intrinsic Calculation For Replimune Group, Inc. (NASDAQ:REPL) Suggests It's 24% Undervalued
https://finance.yahoo.com/news/intrinsic-calculation-replimune-group-inc-104004139.html
 Bullish
Yahoo News
Replimune Shares Initial Primary Analysi...
https://finance.yahoo.com/news/replimune-shares-initial-primary-analysis-120000897.html
 Neutral
Macroaxis News: globenewswire.com
Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023
https://www.globenewswire.com/news-release/2023/11/13/2779167/0/en/Forbion-co-leads-129-million-Series-A-financing-of-VectorY-one-of-the-largest-private-biotech-financings-in-Europe-in-2023.html
 Bullish

Replimune Group Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Replimune and other traded companies coverage with news coverage. We help investors stay connected with Replimune headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Replimune Stock performance. Please note that trading solely based on the Replimune Group hype is not for everyone as timely availability and quick action are needed to avoid losses.
Replimune's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Replimune Group investors visualize upcoming and past events in order to time the market based on Replimune Group noise-free hype analysis.
Replimune stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Replimune earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Replimune that are available to investors today. That information is available publicly through Replimune media outlets and privately through word of mouth or via Replimune internal channels. However, regardless of the origin, that massive amount of Replimune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Replimune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Replimune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Replimune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Replimune alpha.

Replimune Largest EPS Surprises

Earnings surprises can significantly impact Replimune's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-11-14
2018-09-30-0.2-0.26-0.0630 
2023-05-18
2023-03-31-0.67-0.74-0.0710 
2021-08-06
2021-06-30-0.46-0.53-0.0715 
2023-08-03
2023-06-30-0.84-0.750.0910 
2024-11-05
2024-09-30-0.77-0.67530.094712 
2020-02-13
2019-12-31-0.36-0.46-0.127 
View All Earnings Estimates

Replimune Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Replimune Group Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Macroaxis News
13th of March 2025
Acquisition by Andrew Schwendenman of 17775 shares of Replimune subject to Rule 16b-3
at MacroaxisInsider 
Yahoo News
7th of March 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635
at finance.yahoo.com 
seekingalpha News
12th of February 2025
Replimune Group GAAP EPS of -0.79 misses by 0.07
at seekingalpha.com 
Gurufocus Stories at Macroaxis
7th of February 2025
Replimune Group Inc Announces Inducement Equity Awards for New Employees
at gurufocus.com 
Yahoo News
21st of January 2025
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 f...
at finance.yahoo.com 
news
19th of December 2024
Sushil Patel Sells 10,000 Shares of Replimune Group, Inc. Stock
at thelincolnianonline.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Replimune in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Replimune's short interest history, or implied volatility extrapolated from Replimune options trading.
When determining whether Replimune Group is a strong investment it is important to analyze Replimune's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Replimune's future performance. For an informed investment choice regarding Replimune Stock, refer to the following important reports:
Check out Replimune Backtesting and Replimune Hype Analysis.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.07)
Return On Assets
(0.26)
Return On Equity
(0.51)
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.